📊 ZBH Key Takeaways
Is Zimmer Biomet Holdings, Inc.. (ZBH) a Good Investment?
Zimmer Biomet demonstrates solid operational fundamentals with strong cash generation (1.5B FCF, 17.9% FCF margin) and healthy balance sheet metrics (1.98x current ratio, 0.55x debt/equity). However, the exceptional 2911% revenue growth appears anomalous and requires investigation into accounting adjustments or business combination impacts, warranting cautious optimism pending clarification of organic vs. inorganic growth drivers.
Zimmer Biomet shows solid underlying cash generation and a generally sound balance sheet, with strong free cash flow, acceptable leverage, and adequate liquidity. However, profitability is only moderate for a medical device company, EPS declined materially year over year, and the reported revenue surge appears low quality or distorted relative to flat net income, which makes the growth profile less convincing.
Why Buy Zimmer Biomet Holdings, Inc.. Stock? ZBH Key Strengths
- Robust free cash flow generation of $1.5B with 17.9% FCF margin demonstrates operational efficiency
- Conservative leverage profile with 0.55x debt/equity and 4.9x interest coverage provides financial flexibility
- Healthy liquidity position with 1.98x current ratio and 1.10x quick ratio indicates ability to meet short-term obligations
- Significant insider buying activity with 39 Form 4 filings in 90 days suggests management confidence
- Strong free cash flow generation with a 17.9% FCF margin supports debt service and strategic flexibility
- Liquidity appears healthy, with a 1.98x current ratio and 1.10x quick ratio
- Leverage is manageable overall, with debt-to-equity of 0.55x and positive operating income
ZBH Stock Risks: Zimmer Biomet Holdings, Inc.. Investment Risks
- Extreme 2911% YoY revenue growth is highly irregular and likely driven by accounting adjustments or acquisition rather than organic growth
- Low profitability margins (8.6% net margin, 15.6% gross margin) are concerning for a medical device company and suggest competitive pressure or integration challenges
- Diluted EPS declined 19.9% YoY despite flat net income, indicating significant share dilution from potential acquisitions
- Weak return metrics (5.6% ROE, 3.1% ROA) suggest suboptimal capital deployment despite strong cash flow generation
- Large long-term debt of $6.9B relative to stockholders equity indicates acquisition-related leverage that may constrain future flexibility
- Reported revenue growth is inconsistent with flat net income, raising concerns about comparability or growth quality
- Profitability metrics are only middle-of-the-road, with 15.6% gross margin and 8.6% net margin
- Interest coverage of 4.9x and long-term debt of $6.93B leave less room if operating performance weakens
Key Metrics to Watch
- Organic vs. inorganic revenue breakdown to validate sustainability of growth rate
- Gross margin trend and product mix shift to assess competitive positioning
- Return on invested capital (ROIC) improvement as integration of acquisitions matures
- Debt reduction trajectory and free cash flow allocation between debt paydown and capital investment
- Operating margin expansion potential through synergy realization
- Operating margin and diluted EPS trend
- Free cash flow consistency and interest coverage
Zimmer Biomet Holdings, Inc.. (ZBH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Zimmer Biomet Holdings, Inc.. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
ZBH Profit Margin, ROE & Profitability Analysis
ZBH vs Healthcare Sector: How Zimmer Biomet Holdings, Inc.. Compares
How Zimmer Biomet Holdings, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Zimmer Biomet Holdings, Inc.. Stock Overvalued? ZBH Valuation Analysis 2026
Based on fundamental analysis, Zimmer Biomet Holdings, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Zimmer Biomet Holdings, Inc.. Balance Sheet: ZBH Debt, Cash & Liquidity
ZBH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Zimmer Biomet Holdings, Inc..'s revenue has shown modest growth of 3% over the 5-year period. The most recent EPS of $4.88 reflects profitable operations.
ZBH Revenue Growth, EPS Growth & YoY Performance
ZBH Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.8B | $230.9M | $1.16 |
| Q2 2025 | $1.9B | $152.8M | $0.77 |
| Q1 2025 | $1.9B | $172.4M | $0.84 |
| Q3 2024 | $1.8B | $162.7M | $0.77 |
| Q2 2024 | $1.9B | $209.6M | $1.00 |
| Q1 2024 | $1.8B | $172.4M | $0.84 |
| Q3 2023 | $1.7B | $162.7M | $0.77 |
| Q2 2023 | $1.8B | $153.7M | $0.73 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Zimmer Biomet Holdings, Inc.. Dividends, Buybacks & Capital Allocation
ZBH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Zimmer Biomet Holdings, Inc.. (CIK: 0001136869)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 3, 2026 | 4 | xslF345X06/form4-04032026_080411.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/form4-04022026_080434.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/form4-04022026_080441.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/form4-04022026_080444.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/form4-04022026_080452.xml | View → |
❓ Frequently Asked Questions about ZBH
What is the AI rating for ZBH?
Zimmer Biomet Holdings, Inc.. (ZBH) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (HOLD) with 75% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ZBH's key strengths?
Claude: Robust free cash flow generation of $1.5B with 17.9% FCF margin demonstrates operational efficiency. Conservative leverage profile with 0.55x debt/equity and 4.9x interest coverage provides financial flexibility. ChatGPT: Strong free cash flow generation with a 17.9% FCF margin supports debt service and strategic flexibility. Liquidity appears healthy, with a 1.98x current ratio and 1.10x quick ratio.
What are the risks of investing in ZBH?
Claude: Extreme 2911% YoY revenue growth is highly irregular and likely driven by accounting adjustments or acquisition rather than organic growth. Low profitability margins (8.6% net margin, 15.6% gross margin) are concerning for a medical device company and suggest competitive pressure or integration challenges. ChatGPT: Reported revenue growth is inconsistent with flat net income, raising concerns about comparability or growth quality. Profitability metrics are only middle-of-the-road, with 15.6% gross margin and 8.6% net margin.
What is ZBH's revenue and growth?
Zimmer Biomet Holdings, Inc.. reported revenue of $8.2B.
Does ZBH pay dividends?
Zimmer Biomet Holdings, Inc.. pays dividends, with $190.3M distributed to shareholders in the trailing twelve months.
Where can I find ZBH SEC filings?
Official SEC filings for Zimmer Biomet Holdings, Inc.. (CIK: 0001136869) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ZBH's EPS?
Zimmer Biomet Holdings, Inc.. has a diluted EPS of $3.55.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ZBH a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Zimmer Biomet Holdings, Inc.. has a BUY rating with 75% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is ZBH stock overvalued or undervalued?
Valuation metrics for ZBH: ROE of 5.6% (sector avg: 15%), net margin of 8.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ZBH stock in 2026?
Our dual AI analysis gives Zimmer Biomet Holdings, Inc.. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ZBH's free cash flow?
Zimmer Biomet Holdings, Inc..'s operating cash flow is $1.7B, with capital expenditures of $224.5M. FCF margin is 17.9%.
How does ZBH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 8.6% (avg: 12%), ROE 5.6% (avg: 15%), current ratio 1.98 (avg: 2).